On the treatment of Diabetus mellitus by acid extract of Duodenal Mucous Membrane
Open accessThe DOI matches its Crossref record.
Abstract
The carrying out in the Bio-Chemical Laboratory of the experiments otn the secretion of organic acids in diabetes described in the previous paper supplied an opportuniity for testing the hypothesis that the internal secretion of the pancreas might be stimulated and initiated (similarly to the externial secretion) by a substance of the nature of a hormone or secretin yielded by the duodenal mucous membrane ; and that in certain cases of diabetes the appearance of sugar in the urine might be due to funictional disturbance occasioned by the absence of such an intestinial excitanit of the initernal secretion.The fact that an internal secretion of the pancreas is niecessary for the regulation of carbohydrate metabolism, and that in the absence of this secretion oxidation of dextrose canniot be carried out, with the result that death occurs from acute diabetes, has been clearly proven by the experimenits of Minkowski and v. Mering,; and others on complete and partial panicreas removal, and the history of the subject is too well-known to require detailed description here.It was suggested by Schafer that the formation of the internal pancreatic secretion might possibly bc due to peculiar nests of cells of different form and staining properties to the other secreting cells of the gland.These cells from their isolated appearanice, and after the name of the observer who first described them, are called the 'islets of Langerhans.'
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Gut-hormone derived GIP, secreted from enteroendocrine K-cells in the upper intestine in the duodenum and jejunum mucosae32, was initially discovered to play an integral role in the body’s response to glucose intake33,34 (Textbox).”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [32]
Citations
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Influenced by the work of Bayliss and Starling, Moore hypothesized that the intestinal mucosa membrane produces a substance of the nature of a hormone that decreases blood glucose via its stimulatory action on the pancreas [55].”
BackgroundInfluentialKieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“Moore (1906) also described experiments carried out on individual young diabetic patients to whom he gave, by mouth, extracts of intestinal mucosa.”
BackgroundGIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
FEHMANN, H.-C., GÖKE, R., & GÖKE, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-390 · Cited by 528
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“Building upon the work of Minkowski and Mering (613), in 1906 Benjamin Moore, Edward Edie, and John Hill Abram reported that repeated daily oral administration of pig-derived intestinal mucosa homogenate reduced urinary glucose in patients with diabetes (437).”
BackgroundResultGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“In 1906, Moore and his colleagues tested the hypothesis that the pancreas might be stimulated by factors from the gut to help disposal of nutrients and started using porcine small intestine extract to treat diabetic patients (Moore, 1906).”
BackgroundUnger, R. H. (1969) · Archives of Internal Medicine · doi:10.1001/archinte.1969.00300130043007 · Cited by 371
Fehmann, H. C. (1992) · Endocrinology · doi:10.1210/en.130.1.159 · Cited by 337
Unger, R. H., Ketterer, H., Dupré, J., & Eisentraut, A. M. (1967) · Journal of Clinical Investigation · doi:10.1172/jci105565 · Cited by 337
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
“, who demonstrated glucose-lowering effects of duodenal extracts in a patient with diabetes [1].”
BackgroundSeino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Oral Glucose Augmentation of Insulin Secretion
Andersen, D. K., Elahi, D., Brown, J. C., Tobin, J. D., & Andres, R. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109100 · Cited by 240
“stances modify glucose metabolism (1).”
Gastric Inhibitory Polypeptide: the neglected incretin revisited
Meier, J. J., Nauck, M. A., Schmidt, W. E., & Gallwitz, B. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00039-3 · Cited by 226
Makrilakis, K. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16152720 · Cited by 216
“The hypothetical existence of certain factors produced by the intestinal mucosa in response to nutrient ingestion that are capable of stimulating the release of insulin from the endocrine pancreas and thereby reducing blood glucose levels was first postulated in the early 1900s [10].”
BackgroundGrossman, M. I. (1974) · Gastroenterology · doi:10.1016/s0016-5085(19)32802-1 · Cited by 221
Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Nauck, M. A., Baller, B., & Meier, J. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s190 · Cited by 163
“The study of gut hormones as stimulators of secretion of the endocrine pancreas has a long history, probably starting with attempts to therapeutically administer intestinal mucosal extracts (containing putative insulinotropic hormones) in patients with diabetes (1).”
BackgroundMetabolic messengers: glucagon-like peptide 1
Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199
Anti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
“A prominent example is, for example, the observation that pig-derived intestinal mucose homogenate decreases glucosuria in patients with diabetes, suggesting that gastrointestinal hormones regulate pancreatic glucose metabolism (Moore, 1906).”
BackgroundVerspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Glycaemic control in type 2 diabetes: Targets and new therapies
Tahrani, A. A., Piya, M. K., Kennedy, A., & Barnett, A. H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.11.001 · Cited by 190
Yabe, D., & Seino, Y. (2011) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2011.07.010 · Cited by 188
“that administration of gut extracts reduces the amount of urine sugars in patients with diabetes, presumably through stimulation of endocrine pancreas (Moore, 1906).”
BackgroundDupre, J., Curtis, J. D., Unger, R. H., Waddell, R. W., & Beck, J. C. (1969) · Journal of Clinical Investigation · doi:10.1172/jci106032 · Cited by 190
Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes
Gautier, J.-F., Choukem, S.-P., & Girard, J. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73397-4 · Cited by 183
“The concept that factors secreted from the gut participate to the regulation of endocrine secretion was raised as early as the beginning of the 20th century [1].”
Reappraisal of GIP Pharmacology for Metabolic Diseases
Finan, B., Müller, T. D., Clemmensen, C., Perez-Tilve, D., DiMarchi, R. D., & Tschöp, M. H. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.03.005 · Cited by 180
Gut hormones and diabetes mellitus
Creutzfeldt, W., & Nauck, M. (1992) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610080206 · Cited by 176
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171
Gautier, J., Fetita, S., Sobngwi, E., & Salaün-Martin, C. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70190-8 · Cited by 163
“The idea that factors secreted from the gut participate to the regulation of endocrine secretion was raised as early as the beginning of the XX century [1].”
Molecular mechanisms underlying nutrient-stimulated incretin secretion
Parker, H. E., Reimann, F., & Gribble, F. M. (2010) · Expert Reviews in Molecular Medicine · doi:10.1017/s146239940900132x · Cited by 155
From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
Holst, J. J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00260 · Cited by 147
“The DPP-4 inhibitors which have already conquered a massive share of the global market are likely to remain keep their status in the years to come in spite of their lesser efficacy for two important reasons (1) their price is gradually falling and (2) their unusually benign side effect profile (124).”
BackgroundInfluentialEffects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00188-2 · Cited by 144
Transforming obesity: The advancement of multi-receptor drugs
Kusminski, C. M., Perez-Tilve, D., Müller, T. D., DiMarchi, R. D., Tschöp, M. H., & Scherer, P. E. (2024) · Cell · doi:10.1016/j.cell.2024.06.003 · Cited by 126
Ebert, R., & Creutzfeldt, W. (1980) · Diabetologia · doi:10.1007/bf00275269 · Cited by 138
“Such cases confirm Moore ' s original hypothesis f rom the year 1906 that "in certain cases of diabetes the appearance of sugar in the urine might be due to functional disturbance occasioned by the absence of an intestinal excitant of the internal secretion" [40].”
BackgroundThe gastrointestinal stimulus to insulin release
Chisholm, D. J., Young, J. D., & Lazarus, L. (1969) · Journal of Clinical Investigation · doi:10.1172/jci106111 · Cited by 122
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors In the Management of Diabetes.
Pathak, R., & Bridgeman, M. B. (2010) · PubMed · Cited by 179
DPP-4 Inhibition and the Path to Clinical Proof
Åhrén, B. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00376 · Cited by 138
GLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
“The incretin concept emerged from the observation that oral administration of an extract of pig duodenal mucosa could reduce hyperglycemia in diabetic patients [2].”
BackgroundThe [pre-] history of the incretin concept
Creutzfeldt, W. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.08.004 · Cited by 123
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0014-9 · Cited by 112
The Origin and Understanding of the Incretin Concept
Rehfeld, J. F. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00387 · Cited by 102
Gupta, V., & Kalra, S. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.85583 · Cited by 95
“Amplification of this incretin effect forms the basis of several incretin-based therapies.[14-19]”
BackgroundInfluentialGlucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Rehfeld, J. F. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2010.02235.x · Cited by 98
“Already Starling, the co-discoverer of secretin, considered the possibility that secretin – in addition to its effect on pancreatic exocrine secretion – might stimulate the ‘internal secretion’ of the pancreas (Starling 1905, Moore et al. 1906).”
BackgroundImmunoreactive Gastric Inhibitory Polypeptide*
KRARUP, T. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-1-122 · Cited by 96
Control of insulin secretion by GLP-1
Jones, B. J., Bloom, S. R., Buenaventura, T., Tomás, A., & Rutter, G. A. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.013 · Cited by 105
Effect of GIP and GLP-1 antagonists on insulin release in the rat
Tseng, C.-C., Zhang, X.-Y., & Wolfe, M. M. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.6.e1049 · Cited by 95
“THE EXISTENCE of chemical stimulants of endocrine pancreatic function in the gastrointestinal tract has been suggested since the beginning of this century (19).”
BackgroundIncretins in obesity and diabetes
Chia, C. W., & Egan, J. M. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14211 · Cited by 93
“In the latest consensus report by the American Diabetes Association and the European Association for the Study of Diabetes published in October 2018, GLP-1R agonists have been recommended as part of glycemic management for the following: (1) patients with established atherosclerotic cardiovascular disease (specificall…”
BackgroundIncretins and the development of type 2 diabetes
Meier, J. J., & Nauck, M. A. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0034-7 · Cited by 105
The incretin hormone GLP‐1 and mechanisms underlying its secretion: 肠促胰岛素激素GLP‐1及其潜在的分泌机制
Tian, L., & Jin, T. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12439 · Cited by 94
“After Starling had coined the term “hormone”, Moore claimed that gut extracts may contain a hormone and showed that the administration of gut extracts could reduce urine sugar levels in diabetic patients.(5)”
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Tschöp, M., Nogueiras, R., & Ahrén, B. (2023) · Diabetologia · doi:10.1007/s00125-023-05929-0 · Cited by 92
Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 91
“Indeed, it has been estimated that just 10-15% of the secreted GLP-1(7-36)NH2 reaches the systemic circulation (117), with some authors reportingmeager peripheral meal-induced changes in both healthy and diabetic people (118).”
BackgroundInfluentialGastrointestinal peptides and insulin secretion
Ebert, R., & Creutzfeldt, W. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030101 · Cited by 99
Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E. M. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 83
Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
Meier, J. J., & Nauck, M. A. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.007 · Cited by 82
EFFECT OF SECRETIN ON INSULIN SECRETION
Unger, R. H., Ketterer, H., Eisentraut, A. M., & Dupré, J. (1966) · The Lancet · doi:10.1016/s0140-6736(66)91749-1 · Cited by 78
GLP1 and cancer: friend or foe?
Vangoitsenhoven, R., Mathieu, C., & Van der Schueren, B. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-12-0111 · Cited by 73
“They are all based on the so-called incretin effect, known since the early 1900s (Bayliss & Starling 1902, Moore 1906; see below).”
The incretins: a link between nutrients and well-being
Burcelin, R. (2005) · British Journal of Nutrition · doi:10.1079/bjn20041340 · Cited by 70
Signaling Mechanisms Underlying the Release of Glucagon-Like Peptide 1
Reimann, F., Ward, P. S., & Gribble, F. M. (2006) · Diabetes · doi:10.2337/db06-s010 · Cited by 68
“(1) first reported the successful use of acid extracts of porcine duodenal mucosa to treat three diabetic patients.”
BackgroundSecretin: A Long Progress Note
Hubel, K. A. (1972) · Gastroenterology · doi:10.1016/s0016-5085(72)80186-0 · Cited by 71
Why Does the Gastric Bypass Control Type 2 Diabetes Mellitus?
Pories, W. J. (1992) · Obesity Surgery · doi:10.1381/096089292765559891 · Cited by 67
Suppressive effect of secretin upon pancreatic alpha cell function
Santeusanio, F., Faloona, G. R., & Unger, R. H. (1972) · Journal of Clinical Investigation · doi:10.1172/jci106975 · Cited by 62
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 56
“Previous studies suggested that factors from the gut provoke the pancreas to aid in nutrient assimilation, which laid the foundation for the treatment of diabetic patients using extracts from porcine small intestine [5].”
BackgroundThe entero-insular axis: implications for human metabolism
Ranganath, L. R. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.008 · Cited by 71
Meier, J. J., Gallwitz, B., & Nauck, M. A. (2003) · BioDrugs · doi:10.2165/00063030-200317020-00002 · Cited by 67
Incretin actions beyond the pancreas: lessons from knockout mice
Yabe, D., & Seino, Y. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.013 · Cited by 57
“Moore demonstrated that gut extracts reduced urine sugars in diabetic patients, presumably by stimulating the endocrine pancreas [2].”
BackgroundGastrointestinal Hormones and Insulin Secretion
Rehfeld, J. F. (1972) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365527209180744 · Cited by 52
Gastric Inhibitory Polypeptide: Physiology and Novel Aspects
Flaten, O. (1983) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528309181548 · Cited by 49
A role for the gut-to-brain GLP-1-dependent axis in the control of metabolism
Burcelin, R., Sérino, M., & Cabou, C. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.09.003 · Cited by 52
Gastro-intestinal hormones GIP and GLP-1
Kieffer, T. J. (2004) · Annales d Endocrinologie · doi:10.1016/s0003-4266(04)95625-9 · Cited by 49
“[59] proposed that the duodenum produced a ‘chemical excitant’of pancreatic secretion and attempted to treat diabetes by injecting gut extracts.”
BackgroundDPP-4 Inhibitors in Clinical Practice
Palalau, A. I., Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2079 · Cited by 44
“intestinal factors are secreted in response to nutrients that can lower blood glucose levels.(36,37) These factors were named “incretins” in the 1930s.”
BackgroundGLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“used extracts from the duodenal mucous membrane to treat T2DM [121].”
MethodGlucose-Dependent Insulinotropic Polypeptide in Incretin Physiology: Role in Health and Disease
Wolfe, M. M., Boylan, M. O., & Chin, W. W. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf006 · Cited by 48
“The existence of an “insulinogenic factor” was initially suggested by Moore et al in 1906, who suggested that the duodenum “supplies a chemical excitant for the internal secretion of the pancreas” (8).”
Pleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 46
Hormonal control of pancreatic endocrine and exocrine secretion.
Youngs, G. R. (1972) · Gut · doi:10.1136/gut.13.2.154 · Cited by 42
Evolution of Neuroendocrine Tumor Therapy
O’Dorisio, T. M., Harris, A. G., & O'Dorisio, M. S. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.11.002 · Cited by 48
On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.
Vilsbøll, T. (2004) · PubMed · Cited by 44
The Hepatic Extraction of Gastric Inhibitory Polypeptide and Insulin*
Hanks, J. B., Andersen, D. K., Wise, J., Putnam, W., Meyers, W. C., & Jones, R. S. (1984) · Endocrinology · doi:10.1210/endo-115-3-1011 · Cited by 35
Gastric Operations and Glucose Homeostasis
Breuer, R. I., Moses, H., Hagen, T. C., & Zuckerman, L. (1972) · Gastroenterology · doi:10.1016/s0016-5085(72)80078-7 · Cited by 36
Glucagon‐like peptide‐1: modulator of β ‐cell dysfunction and death
Rondas, D., D'Hertog, W., Overbergh, L., & Mathieu, C. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12165 · Cited by 32
“This idea was pursued, among others, by Moore, Zunz and Labarre [2–4] who attempted to treat diabetes by injecting gut extracts and introduced the term ‘incretin’ to describe the humoral activity of the gut that enhances the endocrine secretion of the pancreas [4].”
ResultGlucose-dependent insulinotropic polypeptide stimulates the proliferation of colorectal cancer cells
Prabakaran, D., Wang, B., Feuerstein, J. D., Sinclair, J. A., Bijpuria, P., Jepeal, L. I., & Wolfe, M. M. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.04.005 · Cited by 29
Pelle, M. C., Provenzano, M., Zaffina, I., Pujia, R., Giofrè, F., Lucà, S., Andreucci, M., Sciacqua, A., & Arturi, F. (2021) · Life · doi:10.3390/life12010029 · Cited by 28
“The discovery of the incretin dates to 1929 due to the work of La Barre [1], but the true pioneers of the incretin concept were Bayliss and Moore 20 years earlier, when they hypothesized that the endocrine pancreas secretion was regulated by hormones contained in the gut extracts [2,3].”
BackgroundThe physiology and pharmacology of incretins in type 2 diabetes mellitus
Holst, J. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00920.x · Cited by 28
Mutt, V. (1982) · Vitamins and hormones · doi:10.1016/s0083-6729(08)61138-3 · Cited by 31
Über die pharmakodynamischen Wirkungen und chemischen Eigenschaften des Secretins1
Ågren, G. (1934) · Skandinavisches Archiv Für Physiologie · doi:10.1111/j.1748-1716.1934.tb01106.x · Cited by 27
Seeking satiety: From signals to solutions
Tschöp, M. H., & Friedman, J. M. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh4453 · Cited by 30
“This was followed by other studies using parabiosis (cross-circula-tion studies) connecting the pancreatic and the jugular veins in normal and pancreatectomized dogs to show that a circulating intestinal signal could lower blood glucose ( 31 – 33 ).”
MethodInsulin-induced attenuation of glucose-stimulated gastric inhibitory polypeptide secretion
Sirinek, K. R., Pace, W. G., Crockett, S. E., O’Dorisio, T. M., Mazzaferri, E. L., & Cataland, S. (1978) · The American Journal of Surgery · doi:10.1016/0002-9610(78)90088-0 · Cited by 25
Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide
Khan, R., Tomas, A., & Rutter, G. A. (2020) · Peptides · doi:10.1016/j.peptides.2019.170201 · Cited by 24
The emerging role of the intestine in metabolic diseases
Bradley, W. D., Zwingelstein, C., & Rondinone, C. M. (2011) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2011.578651 · Cited by 30
“The concept that factors secreted from the gut participate in the regulation of endocrine secretion was raised as early as the beginning of the 20th century (Moore, 1906).”
Background8 GIP and the entero-insular axis
Brown, J. C., & Otte, S. C. (1979) · Clinics in Endocrinology and Metabolism · doi:10.1016/s0300-595x(79)80047-x · Cited by 23
Role and mechanism(s) of incretin-dependent therapies for treating diabetes mellitus
Nasr, N. E., & Sadek, K. M. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-18534-2 · Cited by 32
Incretin-Based Therapy and Type 2 Diabetes
Hare, K. J., & Knop, F. K. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00015-1 · Cited by 24
Exenatide: A Novel Approach for Treatment of Type 2 Diabetes
Mikhail, N. E. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000240730.86237.b6 · Cited by 22
“” They administered porcine duodenal extract to 5 diabetic patients, but without clear success.(2) The term “incretin” was initially introduced by LaBarre from Belgium in 1932.”
BackgroundGastrointestinal Hormones and Islet Function
Pfeiffer, E. F., Raptis, S., & Fußgänger, R. (1973) · Springer eBooks · doi:10.1007/978-3-642-80704-6_6 · Cited by 21
Metadata
- Authors
- Moore, B., Edie, E. S., & Abram, J. H.
- Affiliations
- University of Liverpool (GB)
- Carnegie Research Scholar
- Royal Infirmary, Liverpool
- ORCID
- Moore, Benjamin
- Venue
- Biochemical Journal
- Publisher
- Portland Press Ltd.
- Published
- 1906-01-01
- Volume
- 1
- Issue
- 1
- Pages
- 28-38
- ISSN
- 0306-3283 (ISSN-L)
- PMC
- PMC1276119
- OpenAlex
- W2107757312
- Cited by
- 279
- References
- 0
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 11 · 2023: 11 · 2022: 8 · 2021: 4 · 2020: 4 · 2019: 14 · 2018: 8 · 2017: 4 · 2016: 10 · 2015: 8 · 2014: 3 · 2013: 12 · 2012: 7
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemical Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetes mellitus, duodenal mucosa, secretin, pancreatic secretion, pancreatic islets, carbohydrate metabolism, glycosuria, pancreatic hormones, acid extract
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.